|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
29.600 +1.160 (+4.079%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 2,917,692 | -6.264% | 5,518,512 | 5,538,812 | 3,524,143 | 2,364,445 |
| Cost of Sales | (599,284) | 5.079% | (1,085,162) | (991,897) | (577,006) | (369,205) |
| Gross Profit | 2,318,408 | -8.808% | 4,433,350 | 4,546,915 | 2,947,137 | 1,995,240 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (383) | -- | 592 | (92) | 700 | (614) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 9,828 | -- | 9,495 | (3,601) | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,094,955 | -24.180% | 2,350,304 | 2,457,754 | 1,745,089 | 1,177,749 | |
| Taxation | (155,427) | -40.610% | (435,642) | (396,027) | (296,887) | (176,163) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 186 | -- | 174 | 620 | 3,551 | 439 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 939,714 | -20.504% | 1,914,836 | 2,062,347 | 1,451,753 | 1,002,025 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (116,624) | 84.322% | (167,373) | (111,108) | (47,379) | (13,138) |
| Depreciation & Amortisation | 46,469 | 22.703% | 82,246 | 49,486 | 34,175 | 27,628 |
| Directors' Emoluments | -- | -- | -- | 23,516 | 16,596 | 14,161 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 89.000 | -21.930% | 183.000 | 210.000 | 149.000 | 99.000 |
| DPS (cts) | 0.000 | -- | 121.040 | 119.420 | 89.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | 66.142% | 56.867% | 59.732% | -- |
| Cash flow per share ($) | -- | -- | 1.701 | 2.079 | 1.687 | 1.325 |
| NBV per share ($) | 8.814 | -- | 9.255 | 6.913 | 4.384 | 2.848 |
| Remarks: | Real time quote last updated: 20/08/2026 17:33 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 939,714 |
| %Change | -20.504% |
| EPS / (LPS) | RMB 0.890 |
| NBV Per Share (¥) | RMB 8.814 |